177Lu-edotreotide PRRT clinical trials

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

This study compares a new radiation treatment (177Lu-edotreotide PRRT) with a standard drug (Everolimus) for people with certain types of advanced neuroendocrine tumours that affect the gut or pancreas. It aims to see which treatment works better and is safer.